Endogenous immune surveillance senolytic medicines program
preclinicaldrug program · medium · Wed Mar 04 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop novel medicines that activate endogenous immune mechanisms to selectively eliminate senescent cells and treat age-related diseases linked to inflammation, extracellular matrix remodeling, metabolic consequences, and fibrotic consequences.
Novel molecules intended to activate immune surveillance mechanisms responsible for removing senescent cells; public record tags indicate small molecule drug activity.
LifeSpan Vision Ventures announced an investment in Deciduous Therapeutics on October 3, 2023; Synapse profile last updated March 4, 2026 lists Deciduous Therapeutics with pipeline-related tags including small molecule drug.
Invariant natural killer T-cell activation for senescent cell elimination
preclinicaldrug program · high · Wed Sep 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop medicines that activate endogenous immune surveillance mechanisms, specifically invariant natural killer T cells, to selectively eliminate inflammatory senescent cells implicated in age-related disease, inflammation, extracellular matrix remodeling, metabolic consequences, and fibrotic consequences.
Novel compounds intended to activate invariant natural killer T cells and endogenous immune mechanisms for senescent cell clearance.
Patent family publication for compounds activating invariant natural killer T cells, including EP4301374A4 published 2025-09-10 and WO2022187141A1 published 2022-09-09.
A 2021 publication reports that invariant natural killer T cells coordinate removal of senescent cells; supplied material does not provide detailed experimental results.
Endogenous immune surveillance activation senolytic program
preclinicalplatform · high
Develop novel medicines that activate endogenous immune mechanisms to selectively eliminate senescent cells implicated in age-related diseases.
Therapeutic activation of immune surveillance, focused on lipid-activated invariant natural killer T cells, to promote clearance of senescent cells.
Company has publicly described its science and listed a 2021 Cell Med paper showing iNKT-mediated senescent-cell clearance in preclinical models.
Activation of iNKT cells with alpha-galactosylceramide reduced senescent preadipocytes in high-fat-diet mice, improved glucose control, limited senescent-cell accumulation after bleomycin lung injury, decreased lung fibrosis, improved survival, and showed preferential cytotoxicity toward senescent human cells in co-culture.
Endogenous immune surveillance medicines platform
undisclosedplatform · medium
Develop novel medicines that activate endogenous immune mechanisms responsible for eliminating senescent cells across age-related disease classes.
Discovery and development of molecules that activate immune surveillance to selectively remove senescent cells driven by inflammatory secretomes, immune surveillance failure, and extracellular matrix remodeling.
Company states its science focuses on molecules that activate immune surveillance to selectively remove senescent cells; no named clinical candidate or pipeline stage is disclosed in the supplied material.
iNKT activation for lung fibrosis models
exploratoryresearch program · medium
Test whether activating iNKT-mediated immune surveillance can clear senescent cells and improve outcomes in fibrotic lung injury.
Preclinical bleomycin lung-injury mouse model using alpha-galactosylceramide-induced iNKT activation to evaluate senescent-cell accumulation, fibrosis, and survival.
2021 publication reported preclinical efficacy in bleomycin-injured mice.
Alpha-galactosylceramide-induced iNKT activation limited senescent-cell accumulation, decreased lung fibrosis, and improved survival.
iNKT activation for metabolic disease models
exploratoryresearch program · medium
Test whether activating iNKT-mediated immune surveillance can eliminate senescent cells in adipose tissue and improve metabolic dysfunction.
Preclinical high-fat-diet mouse model using alpha-galactosylceramide to activate iNKT cells and assess senescent preadipocyte burden and glucose control.
2021 publication reported preclinical efficacy in chronic high-fat-diet mice.
Alpha-galactosylceramide activation of iNKT cells reduced senescent preadipocytes in white adipose tissue and improved glucose control.
iNKT immune surveillance senolytic program
preclinicaldrug program · high
Activate endogenous immune surveillance mechanisms, specifically invariant natural killer T cells, to selectively eliminate senescent cells implicated in age-related diseases.
Pharmacologic activation of iNKT cells with glycolipid antigen biology, including alpha-galactosylceramide in preclinical disease models, to promote immune-mediated clearance of senescent cells.
Preclinical evidence showed iNKT activation reduced senescent cell burden and improved disease-related outcomes in mouse models of high-fat-diet metabolic dysfunction and bleomycin-induced lung fibrosis.
In chronic high-fat diet mice, alpha-galactosylceramide activation of iNKT cells reduced senescent preadipocytes and improved glucose control. In bleomycin-injured mice, iNKT activation limited senescent cell accumulation, decreased lung fibrosis, and improved survival. Human co-culture experiments suggested preferential iNKT cytotoxicity toward senescent cells is conserved in human cells.
Invariant natural killer T cell senescent-cell clearance research program
exploratoryresearch program · medium
Investigate immune mechanisms by which invariant natural killer T cells coordinate removal of senescent cells.
Research publication on invariant natural killer T cells and senescent-cell removal, aligned with Deciduous Therapeutics' stated focus on endogenous immune surveillance of senescent cells.
Publication listed: Invariant natural killer T cells coordinate removal of senescent cells, 2021.
The supplied publication title reports that invariant natural killer T cells coordinate removal of senescent cells.
